The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Circulating Sclerostin Levels and Bone Turnover in Type 1 and Type 2 Diabetes
Open accessAbstract
CONTEXT: Previous observations showed a condition of low bone turnover and decreased osteoblast activity in both type 1 and 2 diabetes mellitus (DM1 and DM2). Sclerostin is a secreted Wnt antagonist produced by osteocytes that regulates osteoblast activity and thus bone turnover. Its levels increase with age and are regulated by PTH. OBJECTIVES: The aim of the present study was to evaluate circulating sclerostin levels in patients with DM1 or DM2 with normal renal function and to analyze its relationship with PTH, 25-hydroxyvitamin D, and bone turnover markers. DESIGN, AND SETTING: This was a cross-sectional study conducted at a clinical research center. PARTICIPANTS: Forty DM2 and 43 DM1 patients were studied and compared with a reference control group (n = 83). RESULTS: In the overall cohort, sclerostin levels were higher in males than in females and significantly increased with age in both genders. The positive correlation between sclerostin and age was maintained in DM1 but not in DM2 patients. Moreover, sclerostin levels were higher in DM2 than in controls or DM1 patients, and this difference persisted when adjustments were made for age and body mass index. Consistent with previous clinical and experimental observations, sclerostin was negatively associated with PTH in nondiabetic patients (r = -0.30; P < 0.01), independently of age and gender. Conversely, an opposite but nonsignificant trend between PTH and sclerostin was observed in both DM1 (r = 0.26; P = 0.09) and DM2 (r = 0.32; P = 0.07) cohorts. CONCLUSIONS: These findings suggest that sclerostin is increased in DM2. Moreover, the transcriptional suppression of sclerostin production by PTH might be impaired in both DM1 and DM2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Marshall, D., Johnell, O., & Wedel, H. (1996) · BMJ · doi:10.1136/bmj.312.7041.1254 · Cited by 3,709
Dawson-Hughes, B., Harris, S. S., Krall, E. A., & Dallal, G. E. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709043371003 · Cited by 2,277
LDL Receptor-Related Protein 5 (LRP5) Affects Bone Accrual and Eye Development
Gong, Y., Slee, R. B., Fukai, N., Rawadi, G., Roman-Roman, S., Reginato, A. M., Wang, H., Cundy, T., Glorieux, F. H., Lev, D., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00571-2 · Cited by 2,235
Vestergaard, P. (2007) · Osteoporosis International · doi:10.1007/s00198-006-0253-4 · Cited by 1,808
(2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.12.005 · Cited by 1,788
High Bone Density Due to a Mutation in LDL-Receptor–Related Protein 5
Boyden, L. M., Mao, J., Belsky, J., Mitzner, L., Farhi, A., Mitnick, M. A., Wu, D., Insogna, K., & Lifton, R. P. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013444 · Cited by 1,591
Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling
Li, X., Zhang, Y., Kang, H., Liu, W., Liu, P., Zhang, J., Harris, S. E., & Wu, D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413274200 · Cited by 1,366
Little, R. D., Folz, C., Manning, S. P., Swain, P. M., Zhao, S.-C., Eustace, B., Lappe, M. M., Spitzer, L., Zweier, S., Braunschweiger, K., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/338450 · Cited by 1,282
Kato, M., Patel, M. S., Levasseur, R., Lobov, I., Chang, B. H.-J., Glass, D. A., Hartmann, C., Li, L., Hwang, T.-H., Brayton, C. F., et al. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200201089 · Cited by 1,086
van Bezooijen, R. L., Roelen, B. A. J., Visser, A., van der Wee-Pals, L., de Wilt, E., Karperien, M., Hamersma, H., Papapoulos, S. E., ten Dijke, P., & Löwik, C. W. G. M. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031454 · Cited by 892
Cited by
Mechanisms of diabetes mellitus-induced bone fragility
On behalf of the IOF Bone and Diabetes Working Group, Napoli, N., Chandran, M., Pierroz, D. D., Abrahamsen, B., Schwartz, A. V., & Ferrari, S. L. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.153 · Cited by 1,107
Diagnosis and management of bone fragility in diabetes: an emerging challenge
Ferrari, S. L., Abrahamsen, B., Napoli, N., Akesson, K., Chandran, M., Eastell, R., El-Hajj Fuleihan, G., Josse, R., Kendler, D. L., Kraenzlin, M., et al. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4650-2 · Cited by 398
Leslie, W. D., Rubin, M. R., Schwartz, A. V., & Kanis, J. A. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1759 · Cited by 352
The clinical utility of bone marker measurements in osteoporosis
Wheater, G., Elshahaly, M., Tuck, S. P., Datta, H. K., & van Laar, J. M. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-201 · Cited by 322
Hygum, K., Starup-Linde, J., Harsløf, T., Vestergaard, P., & Langdahl, B. L. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0652 · Cited by 320
Metadata
- Authors
- Gennari, L., Merlotti, D., Valenti, R., Ceccarelli, E., Ruvio, M., Pietrini, M. G., Capodarca, C., Franci, M. B., Campagna, M. S., Calabrò, A., Cataldo, D., Stolakis, K., Dotta, F., & Nuti, R.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2012-05
- Volume
- 97
- Issue
- 5
- Pages
- 1737-1744
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1992208052
- Cited by
- 272
- References
- 56
- FWCI
- 26.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Circulating Sclerostin Levels and Bone Turnover in Type 1 and Type 2 Diabetes. https://app.cochat.ai/papers/10.1210/jc.2011-2958
- The paper
- Gennari, L., Merlotti, D., Valenti, R., Ceccarelli, E., Ruvio, M., Pietrini, M. G., Capodarca, C., Franci, M. B., Campagna, M. S., Calabrò, A., Cataldo, D., Stolakis, K., Dotta, F., & Nuti, R. (2012). Circulating Sclerostin Levels and Bone Turnover in Type 1 and Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2011-2958
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.